Abstract
Masahiro Matsui, Chie Saito, Seiji Maeda, Makoto Kuro-o, Kunihiro Yamagata, Keisei Kosaki
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Global, regional, and national burden of chronic kidney disease in adults, 1990–2023, and its attributable risk factors: a systematic analysis for the Global Burden of Disease Study 2023
10.1016/s0140-6736(25)01853-7 · 2025
Cardiovascular disease in chronic kidney disease
10.1161/circulationaha.120.050686 · 2021
Sarcopenia in chronic kidney disease: a narrative review from pathophysiology to therapeutic approaches
10.3390/biomedicines13020352 · 2025
Skeletal muscle complications in chronic kidney disease
10.1007/s11914-022-00751-w · 2022
Management of osteoporosis in CKD
10.2215/cjn.11031017 · 2018
High prevalence of sarcopenia, osteoporosis and osteosarcopenia in patients with chronic kidney disease compared with healthy controls
10.1007/s00198-026-08008-3 · 2026
Association of sarcopenia with mortality and end-stage renal disease in those with chronic kidney disease: a UK Biobank study
10.1002/jcsm.12705 · 2021
Bone mineral density and all-cause mortality in patients with nondialysis chronic kidney disease: results from KNOW-CKD study
10.3390/jcm12051850 · 2023
The therapeutic potential of FGF21 in metabolic diseases: from bench to clinic
10.1038/s41574-020-0386-0 · 2020
Regulation of longevity by FGF21: interaction between energy metabolism and stress responses
10.1016/j.arr.2017.05.004 · 2017
Fibroblast growth factor 21: a regulator of metabolic disease and health span
10.1152/ajpendo.00101.2017 · 2017
Serum levels of fibroblast growth factor-21 are increased in chronic and acute renal dysfunction
10.1111/cen.12380 · 2014
Regulation and potential biological role of fibroblast growth factor 21 in chronic kidney disease
10.3389/fphys.2021.764503 · 2021
Increased fibroblast growth factor-21 in chronic kidney disease is a trade-off between survival benefit and blood pressure dysregulation
10.1038/s41598-019-55643-4 · 2019
Skeletal muscle and bone - emerging targets of fibroblast growth factor-21
10.3389/fphys.2021.625287 · 2021
Association between fibroblast growth factor 21 and bone mineral density in adults
10.1007/s12020-017-1507-y · 2018
Association between serum FGF21 level and sarcopenia in older adults
10.1016/j.bone.2021.115877 · 2021
Revised equations for estimated GFR from serum creatinine in Japan
10.1053/j.ajkd.2008.12.034 · 2009
GFR estimation using standardized serum cystatin C in Japan
10.1053/j.ajkd.2012.07.007 · 2013
Performance of GFR equations in Japanese subjects
10.1007/s10157-012-0704-5 · 2013
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
10.1016/j.kint.2023.10.018 · 2024
Comparison between dual-energy X-ray absorptiometry and bioelectrical impedance analyses for accuracy in measuring whole body muscle mass and appendicular skeletal muscle mass
10.3390/nu10060738 · 2018
Reference values and age differences in body composition of community-dwelling older Japanese men and women: a pooled analysis of four cohort studies
10.1371/journal.pone.0131975 · 2015
The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates
10.1093/gerona/glu010 · 2014
Quantitative ultrasound and bone health in elderly people, a systematic review
10.3390/biomedicines11041175 · 2023
Quantitative ultrasound in the management of osteoporosis: the 2007 ISCD official positions
10.1016/j.jocd.2007.12.011 · 2008
Replacing sedentary time for physical activity on bone density in patients with chronic kidney disease
10.1007/s00774-021-01255-w · 2021
Unresolved referenced work
2022
Relationship between cardiorespiratory fitness and blood pressure in young adults: a mediation analysis of body composition
10.1038/hr.2016.177 · 2017
Mediation analysis
10.1146/annurev.psych.58.110405.085542 · 2007
Circulating fibroblast growth factor 21 links hemodynamics with kidney function in middle-aged and older adults: a mediation analysis
10.1038/s41440-021-00782-3 · 2022
Early-stage chronic kidney disease, insulin resistance, and osteoporosis as risk factors of sarcopenia in aged population: the Fourth Korea National Health and Nutrition Examination Survey (KNHANES IV), 2008–2009
10.1007/s00198-014-2745-y · 2014
Relationship between moderate to severe kidney disease and hip fracture in the United States
10.1681/asn.2005111194 · 2006
Fibroblast growth factor 21 controls mitophagy and muscle mass
10.1002/jcsm.12409 · 2019
Inhibition of growth hormone signaling by the fasting-induced hormone FGF21
10.1016/j.cmet.2008.05.006 · 2008
Role of fibroblast growth factor 21 (FGF21) in undernutrition-related attenuation of growth in mice
10.1210/en.2011-1909 · 2012
Fibroblast growth factor 21 and protein energy wasting in hemodialysis patients
10.1016/j.clnu.2021.01.036 · 2021
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ
10.1073/pnas.1200797109 · 2012
The starvation hormone, fibroblast growth factor-21, extends lifespan in mice
10.7554/elife.00065 · 2012
FGF-21 and skeletal remodeling during and after lactation in C57BL/6J mice
10.1210/en.2014-1083 · 2014
Lower serum fibroblast growth factor 21 levels are associated with normal lumbar spine bone mineral density in hemodialysis patients
10.3390/ijerph17061938 · doi-reference